LamKap Bio beta AG specializes in research and development. It also focuses on licensing and marketing of medical therapies, in particular antibody-based therapies against cancer and diseases of the immune system. The company was founded on December 12, 2017 and is headquartered in Pfäffikon, Switzerland.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Shanghai Jibei Biotechnology Co., Ltd., established on 2016-03-26, The scope of business includes engaging in cell,Technology development in the field of bioengineering expertise,technical consulting,Technical Services,technology transfer,Genetic Testing,Laboratory consumables and reagents,Sales of laboratory instruments,Engaged in the import and export of goods and technology,Research and development of cryogenic biological freezing technology and equipment,Cell Storage Service(Except umbilical cord hematopoietic stem cells,Do not engage in medical diagnosis and treatment services). [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class innovative biologics mainly through the discovery of next-generation multispecific antibodies.

Shenzhen Guochuang Nanobody Technology Co., Ltd., established on 2016-03-07, Business scope includes general business items:biomedical products;Monoclonal antibody product and technology development;Nanobody product and technology development;Biotechnology,Research and Development of Nanotechnology;Import and export;medical instruments,Research and development of consumables,Sales,Technical Services,technology transfer.(law,Except for items prohibited by administrative regulations;law,Projects restricted by administrative regulations must be licensed before they can be operated),The licensing program is:Health Supplies(Does not contain health food)promotion of.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.

FameWave is a privately held biopharmaceutical company developing CM-24, a clinical stage monoclonal antibody targeting CEACAM1, a novel immune checkpoint. Kitov is planning initiation of a Phase I/II study in early 2020 to evaluate the safety and efficacy of CM-24 in combination with an anti PD-1 inhibitor.

Hangzhou Abe Biotechnology Co., Ltd., established on 2007-06-01, Business scope includes biological products,medical instruments(Limited to one category),Technical development of experimental instruments,technical consulting,Technical Services,Achievement transfer;medical instruments(Limited to one category),laboratory apparatus,cosmetic,department store,building materials,decorative material,Primary Edible Agricultural Products(except food,medicine)promotion of.

B Cell Design is a biotechnology company which develops innovative products and breakthrough therapeutic concepts for pharma industries. B Cell Design manufactures through its technological platform and its expertise a portfolio of solutions for in vitro diagnostic companies.Based in Limoges, B Cell Design built strong partnerships with international in vitro diagnostic and pharmaceutical companies.

Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

Research Corporation Technologies, Inc. provides investment related services. It operates as technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production with medical devices. The company was founded in 1987 and is headquartered in Tucson, AZ.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Manufactures pharmaceuticals

Guangxi Shengbaotang Pharmaceutical Industry Co., Ltd. (doing business as Sanpotel Pharmaceutical Co., Ltd.) is a Chinese private company located in Nanning that manufactures and sells genetic drugs and biological products.

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Huadao (Shanghai) Biomedical Co., Ltd. engages in the development of biomedical technology. It also engages in the research and development of pharmaceutical products and provides technology consulting and transfer services. The company was founded by Xue Jun Yu on September 30, 2017 and is headquartered in Shanghai, China.